Jorge Hernando

1 article listing Jorge Hernando in Nature Communications, indexed by Paperzzz from Crossref and OSF.

1. Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial Nature Communications